Corticosteroid Use in Interstitial Lung Disease: Evidence‑Based Recommendations

1. Indications for Corticosteroids

• Systemic autoimmune rheumatic disease‑associated ILD (SARD‑ILD) is conditionally recommended for glucocorticoid therapy, whereas systemic sclerosis‑ILD (SSc‑ILD) and idiopathic pulmonary fibrosis (IPF) are strongly contraindicated – the American College of Rheumatology (ACR) guideline (conditional for SARD‑ILD; strong contraindication for SSc‑ILD and IPF) 1.
• Glucocorticoids are conditionally recommended as first‑line therapy for rheumatoid arthritis‑ILD, inflammatory myositis‑ILD, Sjögren’s disease‑ILD, and mixed connective tissue disease‑ILD – ACR guideline (conditional) 1.
• Pulse intravenous methylprednisolone is conditionally recommended as first‑line treatment for rapidly progressive ILD in SARD – ACR guideline (conditional) [2][1].

2. Contraindications and Strong Recommendations Against Steroids

• Strong recommendation against using glucocorticoids as first‑line treatment for SSc‑ILD – ACR guideline (strong) 1.
• Strong recommendation against long‑term glucocorticoid therapy for progressive SSc‑ILD, even when disease is advancing – ACR guideline (strong) [2][1].

3. Dosing Strategies (Historical Context)

• Historical practice employed oral prednisone 40–100 mg daily for 2–4 months, but no comparative dosing trials exist – American Thoracic Society (ATS) expert consensus (observational evidence) 3.

4. Steroid‑Sparing Immunosuppressive Options

• Rituximab, cyclophosphamide, mycophenolate mofetil, and azathioprine are conditionally recommended as first‑line steroid‑sparing agents for SARD‑ILD – ACR guideline (conditional) 1.

5. Tapering and Maintenance Regimens

• If clinical response occurs (usually within 3 months), taper prednisone guided by objective measures such as dyspnea scores, pulmonary function tests, and HRCT – ATS consensus (conditional) 3.
• Chronic low‑dose prednisone (≈15–20 mg every other day) may be sufficient for maintenance in responders – ATS consensus (conditional) 3.
• A minimum treatment duration of 1–2 years is reasonable for patients with unequivocal response; steroids rarely achieve disease eradication – ATS consensus (conditional) 3.

6. Monitoring, Relapse Management, and High‑Risk Populations

• Relapse or clinical deterioration should prompt dose escalation or addition of an immunosuppressive agent rather than indefinite high‑dose steroids – ATS consensus (conditional) 3.
• Patients >70 years old or those with poorly controlled diabetes, hypertension, severe osteoporosis, or peptic ulcer disease are at high risk for steroid complications; early use of cytotoxic agents (e.g., azathioprine or cyclophosphamide) is advised – ATS consensus (conditional) 3.

7. Recommendations on Long‑Term Steroid Use

• Conditional recommendation against long‑term glucocorticoid therapy for SARD‑ILD progression despite initial treatment – ACR guideline (conditional) [2][1].

8. Integration of Antifibrotic Therapy

• Nintedanib is conditionally recommended as a first‑line antifibrotic for SSc‑ILD and may be added when HRCT shows a predominantly fibrotic pattern despite adequate immunosuppression – ACR guideline (conditional) 1.

Corticosteroid and Immunosuppressive Management in Inflammatory Interstitial Lung Disease

1. Initial Assessment and Contra‑indications

• Before initiating corticosteroids, actively exclude infectious etiologies and lymphoproliferative disorders because immunosuppression can exacerbate these conditions. 4

2. First‑Line Corticosteroid Therapy for Non‑Critical Disease

• For patients with moderate‑to‑severe inflammatory ILD (e.g., cryptogenic organizing pneumonia, acute hypersensitivity pneumonitis, NSIP, CTD‑ILD) presenting with significant pulmonary function test or HRCT abnormalities, start oral prednisone at 0.5–1.0 mg kg⁻¹ day⁻¹, not exceeding 60 mg day⁻¹. 5

3. Mandatory Steroid‑Sparing Immunosuppression

• Mycophenolate mofetil is recommended as the preferred first‑line steroid‑sparing agent for all connective‑tissue‑disease‑related ILD. Initiate 500–1000 mg twice daily and titrate to a target of 1500 mg twice daily. 5
• Azathioprine is an acceptable alternative for myositis‑ILD, mixed connective‑tissue disease‑ILD, rheumatoid‑arthritis‑ILD, or Sjögren’s‑ILD; TPMT activity or genotype should be checked before starting. 5
• For refractory or rapidly progressive disease, add rituximab 1000 mg IV on days 1 and 15. 4
• For refractory or rapidly progressive disease, add cyclophosphamide 500–750 mg m⁻² IV every 4 weeks. 4

4. Monitoring and Follow‑up

• Perform full pulmonary function tests every 3–6 months, especially during the first 1–2 years of therapy, to track disease trajectory. 5
• Conduct regular clinical assessments including functional capacity, resting and exertional pulse oximetry, and multidisciplinary HRCT review with a thoracic radiologist; obtain an echocardiogram when pulmonary hypertension is suspected. 5

5. Antifibrotic Therapy in Progressive Fibrotic Phenotype

• Nintedanib is FDA‑approved for progressive fibrotic ILD and may be added when HRCT shows a predominantly fibrotic pattern despite adequate immunosuppression. 5
• Antifibrotic therapy can be combined with ongoing mycophenolate mofetil or azathioprine without discontinuation of the immunosuppressive agent. 5

6. Contra‑indication of Steroids in Idiopathic Pulmonary Fibrosis (IPF)

• Corticosteroids are not recommended for IPF; there is no evidence supporting benefit and they are associated with harm. 6

7. Evidence from Organizing Pneumonia Cohort

• In a cohort of 30 patients with organizing pneumonia, treatment with prednisone 0.5 mg kg⁻¹ for 3 weeks resulted in significant symptomatic, physiological, and radiologic improvement at 6 weeks post‑discharge. 7